Loratadine and pseudoephedrine sulfate: adverse event reports filed with FDA

616

reports as suspect product

0% of all reports · about 33 a year

22

reports, 12 months to June 2026

20 in the 12 months before

10.2%

marked serious by the reporter

50.8% across the class

1.1%

record death among outcomes, as reported

7 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Loratadine and pseudoephedrine sulfate reports recording the termmedian drug in alpha-adrenergic agonist

1. Drug ineffectivethe medicine did not work as expected31.8%196
2. Insomniadifficulty sleeping14%86
3. Dizzinesslight-headedness or unsteadiness6%37
4. Off label useused for a purpose or in a way not on the label3.9%24
5. Wrong technique in product usage processthe product was used in the wrong way3.1%19
6. Incorrect product administration duration2.9%18
7. Headachehead pain2.8%17
8. Incorrect dose administeredthe wrong dose was given2.6%16
9. Expired product administeredthe product was used past its expiry date2.4%15
10. Blood pressure increaseda raised blood pressure reading2.3%14
11. Hypersensitivityan allergic-type reaction2.3%14
12. Nauseafeeling sick2.1%13
13. Dry mouthdry mouth1.9%12
14. Dysuriapain on passing urine1.8%11
15. Extra dose administered1.8%11
16. Feeling jittery1.6%10
17. Heart rate increaseda fast heart rate reading1.6%10
18. Palpitationsawareness of the heartbeat1.6%10
19. Anxietyanxiety1.5%9
20. Decreased appetitereduced appetite1.5%9
21. Dyspnoeashortness of breath1.5%9
22. Therapeutic response decreasedthe medicine worked less well1.5%9
23. Abdominal discomfortstomach discomfort1.3%8
24. Constipationconstipation1.3%8
25. Depressionlow mood1.3%8
26. Inappropriate schedule of drug administrationthe medicine was taken at the wrong times1.3%8
27. Incorrect drug administration duration1.3%8
28. Fatiguetiredness1.1%7
29. Hypoaesthesianumbness1.1%7
30. Accidental overdosean accidental overdose1%6

Top 30 of 134 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 11 drugs in the alpha-adrenergic agonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 23,291 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 96.8% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 616 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the alpha-adrenergic agonist class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Loratadine and pseudoephedrine sulfate as a suspect or interacting product; reports listing it only as a concomitant medication (62) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.